Florian Wagenlehner

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    OM-Pharma
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    MSD
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Klosterfrau
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    GSK
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    European Association of Urology
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Cerexa
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Calixa
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Bionorica
    Date added:
    Date updated:
    06/29/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    06/29/2022

Pages

Return to Update Series (2022) Lesson 21: The Changing Role of Fluoroquinolones for Prophylaxis and Treatment of Urological Infections